Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

299
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
299
Molecular Models02:00

Molecular Models

44.2K
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
44.2K
Three-Compartment Open Model01:06

Three-Compartment Open Model

1.0K
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
1.0K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

379
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
379
Two-Compartment Open Model: Overview01:05

Two-Compartment Open Model: Overview

639
Multicompartmental models are crucial tools in pharmacokinetics, providing a framework to understand how drugs move within the body. The two-compartment model is a crucial subtype, segmenting the body into central and peripheral compartments. The central compartment represents areas with high blood flow, such as plasma and highly perfused organs like the kidneys and liver, while the peripheral compartment signifies tissues with lower blood flow, like adipose tissue and muscle tissue.
The...
639
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

649
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
649

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Learning Covariate Relations in Disease Progression Models Using Symbolic Neural Networks.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.

The Journal of antimicrobial chemotherapy·2026
Same author

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.

EClinicalMedicine·2026
Same author

Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data.

Journal of pharmacokinetics and pharmacodynamics·2026

Related Experiment Video

Updated: Feb 27, 2026

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

5.0K

Open innovation: Towards sharing of data, models and workflows.

Daniela J Conrado1, Mats O Karlsson2, Klaus Romero1

  • 1Quantitative Medicine, Critical Path Institute, Tucson, AZ, USA.

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|July 8, 2017
PubMed
Summary

Open innovation in pharmacometrics is accelerating, with a focus on sharing data, models, and workflows. This enhances efficiency, transparency, and scientific reliability for drug development.

Keywords:
Data sharingDrug developmentModelling workflowsOpen innovationPharmacometric models

More Related Videos

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

5.0K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Area of Science:

  • Pharmacometrics
  • Computational Biology
  • Drug Development

Background:

  • Open innovation and resource sharing are increasingly adopted by the scientific community.
  • Sharing data, models, and workflows offers benefits like addressing new questions, increased efficiency, and enhanced scientific reliability.
  • The field of pharmacometrics is actively developing initiatives for public sharing of resources.

Purpose of the Study:

  • To highlight the growing trend of open innovation in pharmacometrics.
  • To discuss the challenges and ongoing efforts in sharing pharmacometric data, models, and workflows.
  • To emphasize the need for community ownership in advancing pharmacometric research through open innovation.

Main Methods:

  • Review of current initiatives and organizations involved in pharmacometric resource sharing.
  • Identification of disease-specific databases and model repositories.
  • Discussion of challenges related to data formats, standards, and legal/ethical issues.

Main Results:

  • Several organizations (CDISC, C-Path, IMI, ISoP) are developing standards for pharmacometric data sharing.
  • Numerous disease-specific databases (e.g., ADNI, WWARN, PDS) are being established for drug-disease modeling.
  • A dedicated model repository (DDMoRe) has been launched, and workflow standardization efforts are underway.

Conclusions:

  • Addressing legal, ethical, and technical challenges is crucial for successful pharmacometric data sharing.
  • Collaborative efforts and standardization are essential for maximizing the impact of pharmacometrics.
  • The scientific community must embrace open innovation to advance drug development and knowledge extraction from clinical data.